News

Alembic Pharma receives US FDA approval for Fesoterodine Fumarate extended-release tabs

The tablets are indicated for treating adults with symptoms of urge urinary incontinence, urgency, and frequency

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Toviaz Extended-Release Tablets, 4 mg and 8 mg, of Pfizer Inc. (Pfizer). Fesoterodine Fumarate Extended-Release Tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses.

THIS CAN BE YOUR ADVERTISEMENT

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg have an estimated market size of $225 million for twelve months ending September 2021 according to IQVIA.

Alembic has received year to date (YTD) 20 approvals (14 final approvals and 6 tentative approvals) and a cumulative total of 159 ANDA approvals (137 final approvals arid 22 tentative approvals) from the US FDA.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close